Myriad Genetics, Inc.

Myriad Genetics is a clinical laboratory and precision medicine company specializing in genetic and genomic testing for hereditary cancer risk, oncology, reproductive health, urology, and mental health. The company operates five primary service lines: (1) Hereditary Cancer Risk—germline testing to identify predisposition to 11 hereditary cancers; (2) Oncology—tumor genomic profiling and companion diagnostics for treatment selection; (3) Reproductive Health—carrier screening and prenatal genetic testing; (4) Urology—prostate cancer prognostic testing; and (5) Mental Health/Pharmacogenomics—testing to guide psychotropic medication selection. Founded over 30 years ago, Myriad maintains one of the largest ancestry-diverse genomic databases and emphasizes clinically actionable, easily interpretable reporting. The company operates CLIA-certified laboratories and serves patients and healthcare providers across the United States and internationally through multiple service centers. All major test products are designed to inform clinical decision-making at points of detection, treatment initiation, and disease prevention. Myriad maintains robust infrastructure for provider ordering, patient support, genetic counseling, and financial assistance programs.